These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-004285-13 A double-blind, placebo-controlled, dose-ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms. 2008-05-08 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-004286-33 An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms. 2009-02-26 bad-data
Reported results Terminated 2014-004363-21 A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followe... 2016-11-30 due-trials
Completed, but no date, and reported results 2015-001324-36 A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy Studio pilota, multicentrico, in aperto con ganaxolone in bambine affette da epiless... bad-data
Listed as ongoing, but also has a completion date 2018-001180-23 A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by L... 2023-08-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-004496-12 A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)- related epilepsy followed by long-term open-label treatment ... 2022-06-20 bad-data
Listed as ongoing, but also has a completion date 2021-003441-38 A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) 2024-10-15 bad-data